Novozymes A/S announce that Rainer Lehmann has been named CFO and EVP and that he will join the company no later than November 1, 2023. Lars Green has decided to leave the company for personal reasons effective no later than at the end of 2023 and after a good and solid handover. As CFO, Rainer will lead Novozymes' global finance organization and financial activities including business finance, accounting, shared services, tax and treasury, as well as IT, legal affairs and investor relations.

Rainer will be based at the head office in Denmark. Rainer Lehmann has established strong financial acumen and international, strategic leadership in the broader biopharmaceutical market. He has spent a total of more than 20 years at Sartorius, a global German DAX40 company with revenues of EUR 4.2 billion and close to 16,000 employees.

His tenure with Sartorius includes 6 years as CFO and a member of the Executive Board, where he has played a key role in transforming the company into a leading international partner of life science research and the biopharmaceutical industry. He was responsible for Finance, IT, Data- and Business Process Management, Corporate Sourcing as well as the PMI Office. Additionally, Rainer commands strong international experience and has spent roughly 17 years in the United States.

After four years with Novozymes as CFO and EVP, Lars Green has decided to step down to pursue a non-executive career, with no plans to take on a future executive role. Lars will leave the company following a smooth handover to Rainer, and no later than by the end of 2023.